InvestorsHub Logo
Followers 28
Posts 4338
Boards Moderated 1
Alias Born 09/22/2006

Re: None

Wednesday, 03/18/2020 7:30:47 AM

Wednesday, March 18, 2020 7:30:47 AM

Post# of 8555
Charles Duncan of Cantor: HALO PT: $35. Says Daratumumab due for approval in mid 2020 and that herceptin/perjeta approval in later 2020 is "underappreciated".

The more you know, the less you don't know.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News